Data / Form D filings / XERIS PHARMACEUTICALS INC
XERIS PHARMACEUTICALS INC: Form D filings
XERIS PHARMACEUTICALS INC, a pharmaceuticals company in Chicago, IL, filed 10 Form D notices with the SEC between 2011 and 2017. The latest, on May 22, 2017, reports $30.1 million sold of a $45 million offering to 22 investors.
Find out what XERIS PHARMACEUTICALS INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 180 North LaSalle Street, STE 1800, Chicago, IL, 60601
- Phone
- (512) 498-2670
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1346302
The full lists. Form D filings in Illinois: 1,511 rows, $75.55, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 22, 2017 | New notice | $44,999,999 | $30,050,443 | $14,949,556 | 22 | May 17, 2017 | sec.gov |
| Dec 30, 2016 | Amendment | $49,999,995 | $45,005,982 | $4,994,013 | 48 | Dec 31, 2015 | sec.gov |
| Jan 11, 2016 | New notice | $49,999,995 | $41,005,980 | $8,994,015 | 47 | Dec 31, 2015 | sec.gov |
| Sep 29, 2014 | New notice | $14,874,990 | $7,274,592 | $7,600,398 | 56 | Sep 17, 2014 | sec.gov |
| Jul 10, 2013 | Amendment | $3,000,000 | $2,315,000 | $685,000 | 38 | May 25, 2012 | sec.gov |
| Feb 14, 2013 | Amendment | $3,000,000 | $1,750,000 | $1,250,000 | 28 | May 25, 2012 | sec.gov |
| Sep 25, 2012 | Amendment | $3,000,000 | $1,125,000 | $1,875,000 | 20 | May 25, 2012 | sec.gov |
| Jun 8, 2012 | New notice | $3,000,000 | $225,000 | $2,775,000 | 6 | May 25, 2012 | sec.gov |
| Oct 12, 2011 | Amendment | $1,958,748 | $1,837,848 | $120,900 | 19 | Jul 5, 2011 | sec.gov |
| Jul 19, 2011 | New notice | $1,958,748 | $1,298,748 | $660,000 | 17 | Jul 5, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul Edick | Executive Officer, Director | |
| Cary McNair | Director | |
| John Shannon | Executive Officer | |
| Robert Faulker | Director | |
| Navneet Puri | Director | |
| Brad Huckabee | Executive Officer | |
| Jonathan Rigby | Director |
Every Form D from the week of May 22, 2017 · All recent filings in Illinois · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what XERIS PHARMACEUTICALS INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.